1. Home
  2. SII vs COLL Comparison

SII vs COLL Comparison

Compare SII & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SII
  • COLL
  • Stock Information
  • Founded
  • SII 2008
  • COLL 2002
  • Country
  • SII Canada
  • COLL United States
  • Employees
  • SII N/A
  • COLL N/A
  • Industry
  • SII Finance: Consumer Services
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • SII Finance
  • COLL Health Care
  • Exchange
  • SII Nasdaq
  • COLL Nasdaq
  • Market Cap
  • SII 1.1B
  • COLL 947.6M
  • IPO Year
  • SII N/A
  • COLL 2015
  • Fundamental
  • Price
  • SII $65.03
  • COLL $29.58
  • Analyst Decision
  • SII
  • COLL Strong Buy
  • Analyst Count
  • SII 0
  • COLL 5
  • Target Price
  • SII N/A
  • COLL $43.80
  • AVG Volume (30 Days)
  • SII 191.4K
  • COLL 259.1K
  • Earning Date
  • SII 08-06-2025
  • COLL 08-07-2025
  • Dividend Yield
  • SII 1.83%
  • COLL N/A
  • EPS Growth
  • SII 10.23
  • COLL N/A
  • EPS
  • SII 1.93
  • COLL 1.25
  • Revenue
  • SII $180,474,000.00
  • COLL $664,283,000.00
  • Revenue This Year
  • SII $0.57
  • COLL $20.04
  • Revenue Next Year
  • SII $8.89
  • COLL $3.98
  • P/E Ratio
  • SII $33.98
  • COLL $23.59
  • Revenue Growth
  • SII 17.97
  • COLL 17.17
  • 52 Week Low
  • SII $38.41
  • COLL $23.23
  • 52 Week High
  • SII $65.67
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • SII 81.18
  • COLL 51.67
  • Support Level
  • SII $64.14
  • COLL $29.11
  • Resistance Level
  • SII $63.12
  • COLL $30.22
  • Average True Range (ATR)
  • SII 1.18
  • COLL 0.67
  • MACD
  • SII 0.13
  • COLL -0.08
  • Stochastic Oscillator
  • SII 96.46
  • COLL 33.03

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: